The online version of this article (doi:10.1007/s00787-013-0515-6) contains supplementary material, which is available to authorized users.
The objective is to identify attributes of ADHD stimulant medications that influence treatment preferences of parents of children and adolescents with ADHD across six European countries, using a discrete choice experiment (DCE). Different attributes (and associated levels) of stimulant therapies were identified through literature review and clinician input. Attributes included duration and degree of symptom control after each dose, frequency of medication dosing, potential for treatment to be abused, the side effects of vomiting, loss of appetite, and sleep disturbance. Attributes and levels were combined using an orthogonal design to produce a number of discrete hypothetical treatments. Parents were recruited via patient panels in different countries and asked to complete a survey. DCE data were analyzed using conditional logit models to explore the impact of each attribute on participants’ choices. Six hundred individuals (220 parents of adolescents and 380 parents of children) participated. All attributes were significant predictors of choice (p < 0.01). ‘Degree of symptom control’ was the most important attribute whereby the odds of choosing ‘very much improved symptoms’ compared with ‘minimally improved’ was 4.85 [95 % confidence interval (CI) = 4.28–5.49] for the adolescent group and 6.37 (95 % CI = 5.79–7.01) for the child group. Some inter-country differences emerged, e.g., achieving the best degree of symptom control was more important to parents in some countries than others. In conclusion, the study showed that duration and degree of symptom control were the most important aspects of treatment for parents in all countries. The findings revealed cultural differences in the relative importance of attributes.
Supplementary material 1 (DOCX 70 kb)787_2013_515_MOESM1_ESM.docx
American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108:1033–1044 CrossRef
National Institute for Health & Clinical Excellence (2008) Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE, Sept 2008
Preuss U, Ralston SJ, Baldursson G, Falissard B, Lorenzo MJ, Rodrigues Pereira R, Vlasveld L, Coghill D, ADORE Study Group (2006) Study design, baseline characteristics and interventions in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 15:I4–I14 PubMedCrossRef
White BP, Becker-Blease KA, Grace-Bishop K (2006) Stimulant medication use, misuse, and abuse in an undergraduate sample and graduate student sample. J Amer Coll Health 54:261–268 CrossRef
Lloyd A, Dewilde S, Yuen C, Price M et al (2004) The perceived benefits of dosing schedules for children with ADHD. Poster presentation at 7th Annual European Congress of ISPOR, Hamburg, 24–26 Oct 2004
Conner D, Lopez F, Flood E et al (2013) Preferences for non-stimulant ADHD treatment characteristics among children/adolescents with ADHD and their caregivers. In: Hopfer CJ (ed) The Scientific Proceedings of the 2013 Annual Meeting of the American Academy of Child and Adolescent Psychiatry. American Academy of Child and Adolescent Psychiatry, Washington, p 250
Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong LY, von Maltzahn R, Cohen L, Molsen E (2009) Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient reported outcomes translation and linguistic validation good research practices task force report. Value Health 12:430–440 PubMedCrossRef
Rabe-Hesketh S, Skrondal A (2012) Dichotomous or binary responses. Multilevel and longitudinal modeling using Stata, 3rd edn. Stata Press, Texas, pp 557–559
- Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries
- Springer Berlin Heidelberg